Effects of Albendazole in HIV patients who are not on ART

A randomized controlled single blind clinical trial to evaluate efficacy of empirical treatment with Albendazole in delaying disease progression amongst HIV positive ART naÃ¯ve patients at an ART centre of a tertiary care hospital

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/05/014237

Enrollment

160

Registered

2018-05-30

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- HIV positive ART naive

Interventions

Intervention1: Tab Albendazole: Tab Albendazole 400mg OD X 3days Control Intervention1: Placebo: Tab Calcium 500mg ODX 3days

Eligibility

Inclusion criteria

Inclusion criteria: HIV positive adults more than 18yrs of age HIV positive patients not on ART HIV positive patients not meeting WHO clinical criteria for initiation of ART CD4 count >500/mm3 at baseline

Exclusion criteria

Exclusion criteria: Patients who have opportunistic infection

Design outcomes

Primary

Measure	Time frame
Mean change in CD4 countTimepoint: Mean change in CD4 count after 6months and 1 year	—

Secondary

Measure	Time frame
Time to initiation of ARTTimepoint: Time to initiation of ART	—

Countries

India

Contacts

Public ContactDr TS Ramakrishnan

AFMC

ramapragnya@gmail.com9923076680

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026